Extramedullary Acute Myeloid Leukemia (eAML): Retrospective Single Center Cohort Study, Clinicopathological, Molecular Analysis and Survival Outcomes
Launched by KING HUSSEIN CANCER CENTER · Sep 15, 2021
Trial Information
Current as of June 16, 2025
Completed
Keywords
ClinConnect Summary
We retrospectively collected patients demographics ,including clinicopathological and genetic-molecular parameters in patients with extramedullary leukemia between January 2003 till September 2019 from King Hussein cancer center(KHCC) electronic medical records. All potential prognostic factors were identified and compared with worldwide data published previously. Treatment and survival outcomes were studies and analyzed.
Primary endpoint : Overall survival (OS).
Secondary endpoint :
* Progression Free Survival (PFS).
* incidence of extramedullary leukemia.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult subjects aged ≥18 year and up to 75 years
- • Male and females.
- • Initially diagnosed and treated with extramedullary leukemia at KHCC and followed till last encounter.
- • Patients, who underwent an allogeneic stem cell transplant.
- • Period January 2003-September 2019
- Exclusion Criteria:
- • Pediatric patients \<18 year of age
- • Patients, who lost their follow up within study period.
About King Hussein Cancer Center
The King Hussein Cancer Center (KHCC) is a leading comprehensive cancer treatment and research institution located in Amman, Jordan. Founded in 1997, KHCC is dedicated to providing advanced cancer care, promoting innovative research, and enhancing education in oncology. As a prominent clinical trial sponsor, KHCC is committed to improving patient outcomes through rigorous scientific investigation and collaboration with international research entities. The center's multidisciplinary team of experts works to develop and implement cutting-edge clinical trials that contribute to the global fight against cancer, ensuring access to the latest therapies and treatment methodologies for patients in the region and beyond.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Amman, , Jordan
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials